Pila Pharma AB

PILA

SE0015988274

Pharmaceuticals

Delayed Nasdaq Stockholm Other stock markets 05:53:19 2024-07-11 am EDT			5-day change	1st Jan Change
6.68 ^SEK	+10.60%		+39.38%	+322.50%

Apr. 19	Pila Pharma Appoints New CEO, Chief Scientific Officer	MT
Apr. 19	Pila Pharma AB Announces Board and Management Appointments	CI

Pila Pharma - Adjusting For a Capital Injection

May 03, 2022 at 04:31 am EDT

Redeye comments on Pila Pharma’s new pipeline announcement and adjusts its fair value range ahead of an anticipated capital injection.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about Pila Pharma AB

Pila Pharma Appoints New CEO, Chief Scientific Officer	Apr. 19	MT
Pila Pharma AB Announces Board and Management Appointments	Apr. 19	CI
Pila Pharma AB Announces CEO Changes	Apr. 19	CI
Pila Pharma Nominates CEO as Chair	Mar. 21	MT
Pila Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Pila Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Pila Pharma Enters Research Collaboration to Study Heart Disease Treatment in Mice	Nov. 27	MT
Pila Pharma AB Enters Research Collaboration with the Research Group of Professor Dick Wagsater, Uppsala University, Sweden	Nov. 26	CI
Pila Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-25	CI
Pila Pharma AB announced a financing transaction	23-08-23	CI
Pila Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Pila Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Pila Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-28	CI
Pila Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-26	CI
Pila Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
Pila Pharma AB Announces the Preclinical Toxicological Three-Month Studies of the Active Substance Xen-D0501 Has Begun	22-06-30	CI
Pila Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Pila Pharma AB Announces Certification of API	22-04-25	CI
Pila Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-18	CI
PILA PHARMA AB has completed an IPO in the amount of SEK 34.999992 million.	21-07-12	CI
PILA PHARMA AB has filed an IPO in the amount of SEK 34.999992 million.	21-06-15	CI
PILA PHARMA AB acquired TRPV1 antagonists from Ario Pharma Limited.	16-03-29	CI
PILA PHARMA AB announced that it has received funding from Almi Invest AB	15-12-30	CI

Pila Pharma AB is a Sweden-based clinical stage pharmaceutical company, active in the biotechnology sector. The Company conducts clinical tests in phase 2 with drugs against type 2 diabetes. The target product is a tablet that is taken orally in an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. PILA PHARMA's patent-protected product candidate is called XEN-D0501 and is a TRPV1 antagonist, a novel type of oral anti-diabetic agent for treatment of type 2 diabetes. Pila Pharma AB has completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. In addition, the product is expected to have fewer unwanted side effects than alternative forms of treatment.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PILA PHARMA AB	+322.50%	13.63M
ELI LILLY AND COMPANY	+61.22%	846B
NOVO NORDISK A/S	+39.68%	628B
JOHNSON & JOHNSON	-4.66%	360B
MERCK & CO., INC.	+16.77%	322B
ABBVIE INC.	+8.50%	297B
ASTRAZENECA PLC	+14.30%	240B
NOVARTIS AG	+17.85%	223B
ROCHE HOLDING AG	+3.19%	224B
AMGEN INC.	+11.68%	173B

Other Pharmaceuticals

Pila Pharma AB

Equities

PILA

SE0015988274

Pharmaceuticals

Pila Pharma - Adjusting For a Capital Injection

Latest news about Pila Pharma AB

Chart Pila Pharma AB

Company Profile

Income Statement Evolution

Chiffre d''affaires - Rate of surprise

Sector Other Pharmaceuticals